Ricard Mesı́a

Universitat Autònoma de Barcelona — Spain

Medicine · Health Sciences

44h-index20.1kcitations324works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(184), Lung Cancer Treatments and Mutations(92), Cancer Immunotherapy and Biomarkers(67), Cancer Diagnosis and Treatment(42), Head and Neck Surgical Oncology(26)

Publications320 total

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
The Lancet·2025· 2 cited
Figure S1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Data1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Impact of clinical and dosimetric factors on severe oral mucositis in head and neck cancer: insights from a phase II clinical trial
Frontiers in Oncology·2025Open Access
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
Frontiers in Oncology·2025Open Access
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
ESMO Open·2025· 1 citedOpen Access
Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial
Nutrition Journal·2025· 1 citedOpen Access
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era
European Journal of Cancer·2025· 1 cited
Clarifying the consensus on laryngeal preservation strategies – Authors' reply
The Lancet Oncology·2025
Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review
Oral Oncology·2025· 2 citedOpen Access
Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
Clinical and Translational Medicine·2025Open Access
Abstract P3-05-25: Dynamic increases in T cell repertoire diversity determine palbociclib efficacy and improved antitumor immune response
Clinical Cancer Research·2025
Abstract P2-03-28: Immune-based gene expression signature determines clinical efficacy of CDK4/6i in HR+HER2- breast cancer
Clinical Cancer Research·2025
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
Journal of Clinical Oncology·2025· 37 cited
VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Journal of Clinical Oncology·2025· 2 cited
Induction chemotherapy followed by chemoradiotherapy with cisplatin or cetuximab for unresectable locally advanced head and neck cancer (TTCC-2007-01 trial): Analysis of genomic biomarkers by next-generation sequencing after long-term outcomes.
Journal of Clinical Oncology·2025
Supplementary Figure S1 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Supplementary Figure S3 from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
Data from Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025Open Access
page 1 of 16Next →

Frequent Co-authors

Lisa Licitra(11), Éva Remenár(10), Miren Taberna(10), Makoto Tahara(9), Ulrich Keilholz(9), Gilberto de Castro(8), Kevin J. Harrington(7), Richard Greil(7), Denis Soulières(7), Amanda Psyrri(7), Danny Rischin(7), Josep Tabernero(7), Thorsten Fuereder(6), Brett Hughes(6), Jérôme Fayette(6), Joan Brunet(6), Didier Cupissol(5), Frédéric Peyrade(5), Barbara Burtness(5), Caroline Even(5)